Journal Watch · Nature Communications · 2026
Sevuparin in children with severe malaria: a phase I safety and dose-finding trial.
MTD of 3 mg/kg sevuparin in each of three infusions at 0, 8 and 16 h was identified for future investigation.
TL;DR
MTD of 3 mg/kg sevuparin in each of three infusions at 0, 8 and 16 h was identified for future investigation.
Key findings
- The final dose was therefore 3 mg/kg.
- There was 1 death (1/23 (4.3%)), 1 readmission and 1 grade 3 non-DLT adverse event: all judged unrelated to sevuparin.
- MTD of 3 mg/kg sevuparin in each of three infusions at 0, 8 and 16 h was identified for future investigation.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Secondary endpoints were lactate clearance, parasite half-life, APTT at 24 h and grade 3-4 serious adverse events. Twenty-three children were enroled; 20 were included in the primary analysis, across 10 cohorts. A data monitoring committee followed model recommendations, leading to dose escalation from 1.5 mg/kg through all doses to 6 mg/kg when 2 DLTs occurred. During de-escalation, DLTs occurred at 5 mg/kg and 4 mg/kg.
Full abstract (original)
Background: Mortality rates for African children with severe malaria remain high. Sevuparin, a heparin-like compound, as an adjunctive treatment, may improve outcomes due to its effects on Plasmodium falciparum-infected erythrocytes. A Phase I dose-finding trial in Kenyan and Zambian children with severe malaria aimed to identify the maximum tolerated dose (MTD) of sevuparin, given as three infusions (at 0, 8 and 16 h post-enrolment) using the continual reassessment method (ISRCTN32271864). The primary endpoint was dose limiting toxicity (DLT) defined as Activated Partial Thromboplastin Time (APTT) > 95 seconds (2.5x upper limit of normal) across 1.5-6 mg/kg doses.
What they did: Secondary endpoints were lactate clearance, parasite half-life, APTT at 24 h and grade 3-4 serious adverse events. Twenty-three children were enroled; 20 were included in the primary analysis, across 10 cohorts. A data monitoring committee followed model recommendations, leading to dose escalation from 1.5 mg/kg through all doses to 6 mg/kg when 2 DLTs occurred. During de-escalation, DLTs occurred at 5 mg/kg and 4 mg/kg.
Results & conclusions: The final dose was therefore 3 mg/kg. There was 1 death (1/23 (4.3%)), 1 readmission and 1 grade 3 non-DLT adverse event: all judged unrelated to sevuparin. MTD of 3 mg/kg sevuparin in each of three infusions at 0, 8 and 16 h was identified for future investigation.
Abstract © the authors / Nature Communications (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41467-026-78536-3 · PubMed 42907487.
Why it matters for pharma & biotech
- Relevant to General & Medicine teams tracking Nature Communications for new targets, mechanisms and biomarkers.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this Nature Communications study find?
MTD of 3 mg/kg sevuparin in each of three infusions at 0, 8 and 16 h was identified for future investigation.
What type of study is this?
It is a randomised / controlled clinical trial, published in Nature Communications in 2026. Secondary endpoints were lactate clearance, parasite half-life, APTT at 24 h and grade 3-4 serious adverse events.
Where can I read the original paper?
The original is at the publisher via DOI 10.1038/s41467-026-78536-3. PubMed ID: 42907487. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/sevuparin-in-children-with-severe-malaria-a-phase-i-safety-and-dose-find-785363/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides